Recombinant Human FGFR4 (N-GST tag)
Catalog No : IGX-RP841
366.40€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Recombinant Human FGFR4 (N-GST tag) | ||
|---|---|---|---|
| Catalog No | IGX-RP841 | ||
| Supplier’s Catalog No | IGX-RP841 | ||
| Supplier | ImuGeX | ||
| Source antigen | Insect cells | ||
| Reactivity | Human | ||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 65 | ||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | TKF, JTK2, CD334, MGC20292 | ||
| Grade | Highly Purified | ||
| Purity | 70% - 90% | ||
| Form | 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | 70% - 90% | ||
| Description | FGFR4 is a member of the fibroblast growth factor receptor family which play a role in mitogenesis and differentiation . FGFR4 preferentially binds acidic fibroblast growth factor and is overexpressed in gynecological tumor samples, suggesting a role in breast and ovarian tumorigenesis. FGFR4 gene expression is up-regulated in doxorubicin-treated, apoptosis-resistant cancer cell clones . Ectopic expression of FGFR4 in cancer cells leads to reduced apoptosis sensitivity on treatment with doxorubicin or cyclophosphamide, whereas knockdown of endogenous FGFR4 expression in breast cancer cell lines has the opposite effect. | ||
Product Details
© 2020 Imugex All Rights Reserved